Crinetics Pharmaceuticals, Inc. — Director's Dealing 2020

Jun 22, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2020-06-19

Reporting Person: Fust Matthew K (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-19	Stock Option (right to buy)	$23.23	A	12500	Acquired	2030-06-18	Common Stock (12500)	Direct

Footnotes

F1: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.